Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 8,000 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $13.79, for a total value of $110,320.00. Following the completion of the transaction, the chief executive officer now owns 1,080,536 shares in the company, valued at $14,900,591.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Tarsus Pharmaceuticals Stock Down 5.0 %
Shares of Tarsus Pharmaceuticals stock traded down $0.67 during midday trading on Friday, hitting $12.75. The company’s stock had a trading volume of 247,899 shares, compared to its average volume of 74,542. The firm has a market capitalization of $340.04 million, a P/E ratio of -5.00 and a beta of 0.69. The stock has a 50-day simple moving average of $15.07 and a 200-day simple moving average of $15.87. The company has a quick ratio of 16.40, a current ratio of 16.40 and a debt-to-equity ratio of 0.10. Tarsus Pharmaceuticals, Inc. has a 1-year low of $10.80 and a 1-year high of $19.66.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday.
Institutional Trading of Tarsus Pharmaceuticals
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
- Get a free copy of the StockNews.com research report on Tarsus Pharmaceuticals (TARS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.